QuantalX Neuroscience is an Israeli medical device company developing the Delphi-MD, a first-in-class functional neuro-imaging system for the early detection and differential diagnosis of brain disorders. Founded in 2014 by neuroscientists Dr. Iftach Dolev and Dr. Hilla Fogel, the company is headquartered in Kfar Saba, Israel.

The Delphi-MD combines transcranial magnetic stimulation (TMS) with electroencephalography (EEG) to produce real-time functional maps of brain network activity. Patients wear a sensor-equipped EEG cap that records brain responses to magnetic pulses; proprietary software compares the resulting TMS-evoked potentials against an FDA-cleared normative reference database of healthy, age-matched brain responses. The system is non-invasive, radiation-free, requires no active patient participation, and can be administered at the point of care without specialized imaging infrastructure.

QuantalX has received FDA De Novo authorization (establishing a new regulatory category for brain function assessment devices), CE-MDR certification, and Israeli Ministry of Health approval. The system holds FDA Breakthrough Device designations for stroke/dementia risk assessment and Normal Pressure Hydrocephalus diagnosis. Delphi-MD is in clinical use at major Israeli hospitals and at US research institutions including Massachusetts General-Brigham, University of Pennsylvania, UCSF, and University of Illinois Chicago. The company has raised $8.6 million.